Ahead of Alzheimer’s meeting, researchers seize on signs of progress
By Bill Berkrot and Ransdell Pierson NEW YORK (Reuters) – After decades of Alzheimer’s research that led to dead ends, including 123 drugs that failed, top researchers in the field say they are far more confident now of producing an effective treatment. New experimental drugs from Eli Lilly and Co and Biogen have shown promise in slowing down the progression of the mind-wasting disease, attracting the attention of investors and patients. “The recurring platitude, which has been going on forever is ‘gee we’re about five years away from a really effective treatment,'” said Steven Ferris, who directs the Alzheimer’s clinical trials program at NYU Langone Medical Center in New York.
Medications/Drugs News Headlines – Yahoo! News
More From Around the Web
Check out these Articles
- Hopes rise for AstraZeneca cancer drug with start of new trial
- EU agency backs AstraZeneca’s MOVENTIG drug
- Pfizer wins dismissal of U.S. investor class action ahead of trial
- Obama nominates Robert Califf as FDA commissioner
- Former Toronto Mayor Rob Ford moved into palliative care -report
- ‘Drug courts’ scrutinized after shooting of New York City offic...
- Johnson & Johnson: Stelara fares well in Crohn’s disease
- Potential delay on some upgrades to gov’t insurance site
- Chronic marijuana use in teens not linked to later health issues
- Cancer drug labels rarely reflect patient experiences
- Shadowed by Bush, Obama seeks Africa legacy makeover
- Newly released documents show profit-seeking behind price hikes at Turing, ...
- Amgen seeks U.S. approval of new cholesterol-fighting drug